Ft. Myers, Florida - January 9, 2012 - NeoGenomics, Inc.
(NASD OTC BB: NGNM), a leading provider of cancer-focused
genetic testing services, announced today the
appointment of Dr. Maher Albitar as Chief Medical Officer and
Director of Research and Development.
From 2003 to 2010, Dr. Albitar served as the Medical Director
for Hematopathology and Oncology, and Chief of Research and
Development, for Quest Diagnostics Nichols Institute. He was
responsible for the development of numerous tests and
inventions in molecular testing and plasma-based testing.
From 1991 through 2003, Dr. Albitar held various faculty
positions at The University of Texas MD Anderson Cancer
Center where he also served as Director of the Leukemia and
Molecular Laboratory in the Division of Laboratory Medicine
and Pathology Medicine. He was also a tenured full professor
in the Departments of Leukemia and Pathology. Most recently,
Dr. Albitar served as the Chief Medical Officer of Health
Discovery Corporation ("HDC"), and he will remain as a member
of the Board of Directors of HDC.
Dr. Albitar attended medical school at Damascus Medical
School, completed his Anatomic Pathology and Clinical
Pathology Residency at Brown University, and completed a
Hematopathology Fellowship as well as a post-doctoral
training in Genetics at the Howard Hughes Medical Institute
at the University of Pennsylvania. He holds numerous patents
and has authored more than 300 peer-reviewed papers, book
chapters, and review articles. Dr. Albitar has served on a
variety of medical editorial review boards and is a frequent
guest speaker at national and international conferences.
Doug VanOort, Chairman and CEO, commented, "We are delighted
to welcome Dr. Maher Albitar to our company. Our company's
roots are in the diagnosis of hematologic cancers, and Dr.
Albitar is world renowned for his expertise in
Hematopathology and Molecular Oncology. Additionally, Dr.
Albitar's passion for innovation and development of new
molecular genetic tests will enhance our ability to develop
and launch novel new tests targeting a variety of cancers. We
expect innovation and the launch of proprietary products to
be an ever more important driver of future growth for our
company."
1
Dr Albitar commented, "NeoGenomics has established an
excellent reputation as one of the premier cancer testing
laboratories in America and I am honored to join the
executive team. The recent agreement between NeoGenomics and
Health Discovery Corporation provides the perfect environment
for innovation and the development of clinical models based
on pattern recognition and multi-analyte analysis. I look
forward to helping NeoGenomics commercialize a number of new
proprietary laboratory developed tests and other products
based on combining recent developments in molecular
techniques with HDC's pattern recognition technology."
NeoGenomics, Inc. is a high-complexity CLIA-certified clinical laboratory that specializes in cancer genetics diagnostic testing, the fastest growing segment of the laboratory industry. The company's testing services include cytogenetics, fluorescence in-situ hybridization (FISH), flow cytometry, immunohistochemistry, morphology studies, anatomic pathology and molecular genetic testing. Headquartered in Fort Myers, FL, NeoGenomics has labs in Nashville, TN, Irvine, CA and Tampa and Fort Myers, FL. NeoGenomics services the needs of pathologists, oncologists, urologists and other clinicians, and hospitals throughout the United States. For additional information about NeoGenomics, visit http://www.neogenomics.com.
Forward Looking StatementsExcept for historical information, all of the statements, expectations and assumptions contained in the foregoing are forward-looking statements. These forward looking statements involve a number of risks and uncertainties that could cause actual future results to differ materially from those anticipated in the forward looking statements. Actual results could differ materially from such statements expressed or implied herein. Factors that might cause such a difference include, among others, the company's ability to continue gaining new customers, offer new types of tests, and otherwise implement its business plan. As a result, this press release should be read in conjunction with the company's periodic filings with the SEC.
For further information, please contact: NeoGenomics, Inc. Hawk Associates, Inc. Steven C. Jones Ms. Julie Marshall Director of Investor Relations (305) 451-1888
(239) 325-2001 neogenomics@hawkassociates.com sjones@neogenomics.com
2
distribué par | Ce noodl a été diffusé par NeoGenomics Inc. et initialement mise en ligne sur le site http://www.neogenomics.org. La version originale est disponible ici. Ce noodl a été distribué par noodls dans son format d'origine et sans modification sur 2012-01-09 15:21:24 PM et restera accessible depuis ce lien permanent. Cette annonce est protégée par les règles du droit d'auteur et toute autre loi applicable, et son propriétaire est seul responsable de sa véracité et de son originalité. |
Documents associés | |
NeoGenomics Appoints Dr. Maher Albitar as Chief Medical Officer |